Steven C Lin1, Elhamy Heba2, Tanya Wolfson3, Brandon Ang1, Anthony Gamst3, Aiguo Han4, John W Erdman5, William D O'Brien4, Michael P Andre6, Claude B Sirlin2, Rohit Loomba7. 1. NAFLD Translational Research Unit, Division of Gastroenterology, University of California at San Diego, La Jolla, California. 2. Liver Imaging Group, Department of Radiology, University of California at San Diego, La Jolla, California. 3. Computational and Applied Statistics Laboratory, San Diego Supercomputer Center, University of California at San Diego, La Jolla, California. 4. Bioacoustics Research Laboratory, Department of Electrical and Computer Engineering, University of Illinois at Urbana-Champaign, Urbana, Illinois. 5. Department of Food Science and Human Nutrition, University of Illinois at Urbana-Champaign, Urbana, Illinois. 6. Liver Imaging Group, Department of Radiology, University of California at San Diego, La Jolla, California; San Diego Veterans Affairs Healthcare System, San Diego, California. 7. NAFLD Translational Research Unit, Division of Gastroenterology, University of California at San Diego, La Jolla, California; Division of Epidemiology, Department of Family and Preventive Medicine, University of California at San Diego, La Jolla, California. Electronic address: roloomba@ucsd.edu.
Abstract
BACKGROUND & AIMS: Liver biopsy analysis is the standard method used to diagnose nonalcoholic fatty liver disease (NAFLD). Advanced magnetic resonance imaging is a noninvasive procedure that can accurately diagnose and quantify steatosis, but is expensive. Conventional ultrasound is more accessible but identifies steatosis with low levels of sensitivity, specificity, and quantitative accuracy, and results vary among technicians. A new quantitative ultrasound (QUS) technique can identify steatosis in animal models. We assessed the accuracy of QUS in the diagnosis and quantification of hepatic steatosis, comparing findings with those from magnetic resonance imaging proton density fat fraction (MRI-PDFF) analysis as a reference. METHODS: We performed a prospective, cross-sectional analysis of a cohort of adults (N = 204) with NAFLD (MRI-PDFF, ≥5%) and without NAFLD (controls). Subjects underwent MRI-PDFF and QUS analyses of the liver on the same day at the University of California, San Diego, from February 2012 through March 2014. QUS parameters and backscatter coefficient (BSC) values were calculated. Patients were assigned randomly to training (n = 102; mean age, 51 ± 17 y; mean body mass index, 31 ± 7 kg/m(2)) and validation (n = 102; mean age, 49 ± 17 y; body mass index, 30 ± 6 kg/m(2)) groups; 69% of patients in each group had NAFLD. RESULTS: BSC (range, 0.00005-0.25 1/cm-sr) correlated with MRI-PDFF (Spearman ρ = 0.80; P < .0001). In the training group, the BSC analysis identified patients with NAFLD with an area under the curve value of 0.98 (95% confidence interval, 0.95-1.00; P < .0001). The optimal BSC cut-off value identified patients with NAFLD in the training and validation groups with 93% and 87% sensitivity, 97% and 91% specificity, 86% and 76% negative predictive values, and 99% and 95% positive predictive values, respectively. CONCLUSIONS: QUS measurements of BSC can accurately diagnose and quantify hepatic steatosis, based on a cross-sectional analysis that used MRI-PDFF as the reference. With further validation, QUS could be an inexpensive, widely available method to screen the general or at-risk population for NAFLD.
BACKGROUND & AIMS: Liver biopsy analysis is the standard method used to diagnose nonalcoholic fatty liver disease (NAFLD). Advanced magnetic resonance imaging is a noninvasive procedure that can accurately diagnose and quantify steatosis, but is expensive. Conventional ultrasound is more accessible but identifies steatosis with low levels of sensitivity, specificity, and quantitative accuracy, and results vary among technicians. A new quantitative ultrasound (QUS) technique can identify steatosis in animal models. We assessed the accuracy of QUS in the diagnosis and quantification of hepatic steatosis, comparing findings with those from magnetic resonance imaging proton density fat fraction (MRI-PDFF) analysis as a reference. METHODS: We performed a prospective, cross-sectional analysis of a cohort of adults (N = 204) with NAFLD (MRI-PDFF, ≥5%) and without NAFLD (controls). Subjects underwent MRI-PDFF and QUS analyses of the liver on the same day at the University of California, San Diego, from February 2012 through March 2014. QUS parameters and backscatter coefficient (BSC) values were calculated. Patients were assigned randomly to training (n = 102; mean age, 51 ± 17 y; mean body mass index, 31 ± 7 kg/m(2)) and validation (n = 102; mean age, 49 ± 17 y; body mass index, 30 ± 6 kg/m(2)) groups; 69% of patients in each group had NAFLD. RESULTS:BSC (range, 0.00005-0.25 1/cm-sr) correlated with MRI-PDFF (Spearman ρ = 0.80; P < .0001). In the training group, the BSC analysis identified patients with NAFLD with an area under the curve value of 0.98 (95% confidence interval, 0.95-1.00; P < .0001). The optimal BSC cut-off value identified patients with NAFLD in the training and validation groups with 93% and 87% sensitivity, 97% and 91% specificity, 86% and 76% negative predictive values, and 99% and 95% positive predictive values, respectively. CONCLUSIONS: QUS measurements of BSC can accurately diagnose and quantify hepatic steatosis, based on a cross-sectional analysis that used MRI-PDFF as the reference. With further validation, QUS could be an inexpensive, widely available method to screen the general or at-risk population for NAFLD.
Authors: Naga Chalasani; Zobair Younossi; Joel E Lavine; Anna Mae Diehl; Elizabeth M Brunt; Kenneth Cusi; Michael Charlton; Arun J Sanyal Journal: Hepatology Date: 2012-06 Impact factor: 17.425
Authors: Z Permutt; T-A Le; M R Peterson; E Seki; D A Brenner; C Sirlin; R Loomba Journal: Aliment Pharmacol Ther Date: 2012-05-03 Impact factor: 8.171
Authors: An Tang; Justin Tan; Mark Sun; Gavin Hamilton; Mark Bydder; Tanya Wolfson; Anthony C Gamst; Michael Middleton; Elizabeth M Brunt; Rohit Loomba; Joel E Lavine; Jeffrey B Schwimmer; Claude B Sirlin Journal: Radiology Date: 2013-02-04 Impact factor: 11.105
Authors: Mazen Noureddin; Jessica Lam; Michael R Peterson; Michael Middleton; Gavin Hamilton; Thuy-Anh Le; Ricki Bettencourt; Chris Changchien; David A Brenner; Claude Sirlin; Rohit Loomba Journal: Hepatology Date: 2013-10-17 Impact factor: 17.425
Authors: Rohit Loomba; Nicholas Schork; Chi-Hua Chen; Ricki Bettencourt; Ana Bhatt; Brandon Ang; Phirum Nguyen; Carolyn Hernandez; Lisa Richards; Joanie Salotti; Steven Lin; Ekihiro Seki; Karen E Nelson; Claude B Sirlin; David Brenner Journal: Gastroenterology Date: 2015-08-20 Impact factor: 22.682
Authors: Jeremy S Paige; Gregory S Bernstein; Elhamy Heba; Eduardo A C Costa; Marilia Fereirra; Tanya Wolfson; Anthony C Gamst; Mark A Valasek; Grace Y Lin; Aiguo Han; John W Erdman; William D O'Brien; Michael P Andre; Rohit Loomba; Claude B Sirlin Journal: AJR Am J Roentgenol Date: 2017-03-07 Impact factor: 3.959
Authors: Miriam B Vos; Stephanie H Abrams; Sarah E Barlow; Sonia Caprio; Stephen R Daniels; Rohit Kohli; Marialena Mouzaki; Pushpa Sathya; Jeffrey B Schwimmer; Shikha S Sundaram; Stavra A Xanthakos Journal: J Pediatr Gastroenterol Nutr Date: 2017-02 Impact factor: 2.839